REperfusion Therapy for Acute Ischemic STrOke Due to Large aRtEry Occlusion

Launched by BEIJING TIANTAN HOSPITAL · Mar 28, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how effective a specific treatment called mechanical thrombectomy is for patients who have experienced an acute ischemic stroke caused by a blockage in a major blood vessel in the brain. The researchers want to gather information about patients treated within 24 hours of their stroke and learn what factors might influence whether the treatment successfully restores blood flow to the brain. This will help improve future treatments for stroke patients.

To participate, you need to be at least 18 years old and have had certain imaging tests done to confirm that you have a major blood vessel blockage. You must also be able to start treatment within 24 hours of your stroke and have a good level of function before the stroke. If you join the study, you will be monitored over time to see how well the treatment works and if there are any complications. It's important to note that if you have certain medical conditions or are currently involved in other studies, you may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Older than 18 years;
• • Perfusion imaging completed including CTA+CTP or MRA+PWI+DWI before thrombectomy
• • Large vessel occlusion of cerebral anterior circulation (ICA, MCA-M1 or MCA-M2) confirmed by CTA or MRA, planned to receive or received stenting or aspiration thrombectomy
• • Time intervals ≤ 24 hours from stroke onset to groin puncture.(fulfilled the inclusion of DAWN or DEFUSE 3 trial if the time intervals from stroke onset to groin puncture was ≥6 hours)
• • mRS score ≤2 before admission
• • Informed consent obtained for longitudinal enrolled patients, waived of consent for retrospectively included cases
• Exclusion Criteria:
• • Had a history of infective disease, immunity disease, radiotherapy at head or neck, carotid dissection or other carotid disease.
• • Unable to receive CT or MR scan due to heart failure, cardiac pacemaker, metal implants or claustrophobia, etc.
• • Unable to be injected with contrast agent due to allergy, renal dysfunction, etc.
• • Unlikely to adhere to the study protocol or follow-up ( life expectancy ≤ 3 months)
• • Already participated in other drug trials